肿瘤细胞治疗研究
英文原题：Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic.
CAR-T 细胞疗法已被公认为针对某些血液系统恶性肿瘤最有前景的治疗选择之一。
CAR-T 细胞疗法已被公认为对抗某些血液系统恶性肿瘤最有前景的治疗选择之一。然而，在实体瘤方面，同样的临床和商业成功却遥不可及。在这方面，主要的影响因素是肿瘤细胞所施加的敌对环境，导致免疫效应细胞耗竭以及其浸润能力的丧失。发现其潜在机制并开发可靠的应对策略以克服CAR-T无法到达其靶细胞的问题，可能与晚期实体瘤中令人鼓舞的临床结局相关。在此，我们重点阐述系统性给药的CAR-T在前往其靶细胞的过程中所面临的一系列物理和代谢屏障。此外，我们提出精心设计的应对策略和联合疗法，可用于最大化CAR-T疗法对抗实体瘤的治疗获益。
Chimeric antigen receptor T cell (CAR-T) therapy has been recognized as one of the most prosperous treatment options against certain blood-based malignancies. However, the same clinical and commercial success have been out of range in the case of solid tumors. The main contributing factor in this regard is the hostile environment the tumor cells impose that results in the exhaustion of immune effector cells alongside the abrogation of their infiltration capacity. The discovery of the underlying mechanisms and the development of reliable counterstrategies to overcome the inaccessibility of CAR-Ts to their target cells might correlate with encouraging clinical outcomes in advanced solid tumors. Here, we highlight the successive physical and metabolic barriers that systemically administered CAR-Ts face on their journey toward their target cells. Moreover, we propose meticulously-devised countertactics and combination therapies that can be applied to maximize the therapeutic benefits of CAR-T therapies against solid tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。
